Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 4
Submit an article Journal homepage
687
Views
11
CrossRef citations to date
0
Altmetric
Original Articles

Relapsed/refractory diffuse large B-cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for car-T cell therapy

Alice Di Roccoa Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-0985-9623View further author information
ORCID Icon,
Antonio Cuneob Department of Hematology, S. Anna Hospital, University of Ferrara, Ferrara, ItalyView further author information
,
Arianna Di Roccoc Department of Public Health and Infectious Diseases, Sapienza University, Rome, ItalyView further author information
,
Francesco Merlid Hematology, AUSLL/IRCCS Santa Maria Nuova Hospital, Reggio Emilia, ItalyView further author information
,
Giulia De Lucaa Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, ItalyView further author information
,
Luigi Petruccia Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, ItalyView further author information
,
Michela Ansuinellia Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, ItalyView further author information
,
Domenico Pennad Hematology, AUSLL/IRCCS Santa Maria Nuova Hospital, Reggio Emilia, Italy;e Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, ItalyView further author information
,
Francesco Rotondob Department of Hematology, S. Anna Hospital, University of Ferrara, Ferrara, ItalyView further author information
,
Gian Matteo Rigolinb Department of Hematology, S. Anna Hospital, University of Ferrara, Ferrara, ItalyView further author information
,
Mariateresa Giaimof Division of Hematology, Azienda Ospedaliero-Universitaria di Parma, Parma, ItalyView further author information
,
Francesca Ref Division of Hematology, Azienda Ospedaliero-Universitaria di Parma, Parma, ItalyView further author information
,
Alessio Farcomenig Department of Economics and Finance, University of Rome “Tor Vergata”, Rome, ItalyORCID Iconhttps://orcid.org/0000-0002-7104-5826View further author information
ORCID Icon,
Maurizio Martellia Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, ItalyView further author information
&
Robin Foàa Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, ItalyView further author information
 show all
Pages 828-836 | Received 27 Jul 2020, Accepted 05 Nov 2020, Published online: 04 Dec 2020

References

  • Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.
  • Crump M. Management of relapsed diffuse large B-cell lymphoma. Hematol Oncol Clin North Am. 2016;30(6):1195–1213.
  • Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184–4190.
  • Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014;32(31):3490–3496.
  • Van Den Neste E, Schmitz N, Mounier N, et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. Bone Marrow Transplant. 2016;51(1):51–57.
  • Van Den Neste E, Schmitz N, Mounier N, et al. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. Bone Marrow Transplant. 2017;52(2):216–221.
  • Rigacci L, Puccini B, Dodero A, et al. Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study. Ann Hematol. 2012;91(6):931–939.
  • Van Kampen RJ, Canals C, Schouten HC, et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin’s lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol. 2011;29(10):1342–1348.
  • Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20(1):31–42.
  • Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45–56.
  • Abramson JS, Gordon LI, Palomba ML, et al. Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL. J Clin Oncol. 2018;36(15_suppl):7505–7505.
  • Sano D, Lekakis L, Feng L, et al. Safety and Efficacy of axicabtagene ciloleucel (axi-cel) in older patients: results from the US Lymphoma CAR-T consortium. Hematol Oncol. 2019;37(s2):304–305.
  • Jaglowski S, Hu ZH, Zhang Y, et al. Tisagenlecleucel chimeric antigen receptor (CAR) T-cell therapy for adults with diffuse large B cell lymphoma (DLBCL): real world experience from the Center of International Blood and Marrow Transplant Research (CIBMTR) cellular therapy (CT) registry. Blood. 2019;134(Supplement_1):766–766.
  • Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–1808.
  • Cox DR, Oakes D. Analysis of survival data. London: Chapman and Hall; 1984.
  • Thieblemont C, Legouill S, Di Blasi R, et al. Real-world results on CD19 CAR-T cell for 60 french patients with relapsed/refractory diffuse large B cell lymphoma included in a temporary authorization for use (ATU) program. Hemasphere. 2019;3(s1):736–737.
  • Paillassa J, Di Blasi R, Di Bernard S, et al. Causes of non-eligibility for CD19 CAR-T cell immunotherapy in patients with relapse/refractory DLBCL. Experience of Saint-Louis hospital. Hemasphere. 2019;3(s1):556.
  • Paillassa J, Di Blasi R, Chevret S, et al. CD19 CAR-T cell therapy in patients with relapse/refractory DLBCL: retrospective analysis of the eligibility criteria. Blood. 2019;134(Supplement_1):2887–2887.
  • Jacobson CA, Hunter B, Armand P, et al. Axicabtagene ciloleucel in the real-world: outcomes and predictors of response, rsistance and toxicity. Blood. 2018;132(Supplement 1):92–92.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.